Evaluates chromatin scores for variant interpretation in β-thalassemia, suggesting improvements in assessment methods.
CORRECTION NOTICE (v3, 2026-06-05): This version corrects earlier deposits (v1: Feb 2026; v2: Mar 2026) which contained: (1) phantom reference "Sabaté et al., Nature Genetics 2025" (DOI 404 — paper does not exist) — corrected to Sabaté et al. bioRxiv 2024 (DOI: 10.1101/2024.08.09.605990); (2) clinical reclassification recommendation "we propose reclassifying 3 HBB variants from VUS to Likely Pathogenic" — removed, no ACMG-compliant evidence (PS3) exists; (3) AUC 0.977 overclaim — a June 2026 matched-control audit showed this is a consequence-category distribution artifact (within-category AUC ≈ 0.52, chance level); (4) AlphaGenome inconsistency — mock data excluded from all claims. Full correction details: CORRECTION_NOTE.md.
No takes yet. Share an insight, caveat, or question.
Sergey V. Boyko (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: